IMMUNOGEN INC (IMGN)       5.47  +0.2 (+3.8%)

5.47  +0.2 (+3.8%)

US45253H1014 - Common Stock - After market: 5.45 -0.02 (-0.37%)

News Image
3 days ago - FinancialNewsMedia.com

Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope

/PRNewswire/ -- The global ovarian cancer market is projected to continue to grow through the coming several years. The formation of mutational cells or...

News Image
3 days ago - FinancialNewsMedia

Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope

EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END

News Image
13 days ago - Seeking Alpha

IMGN stock, MRSN stock win buy ratings at Truist on ADC prospects (NASDAQ:MRSN)

Truist Securities launched coverage on clinical-stage biotechs Mersana Therapeutics (MRSN) and ImmunoGen (IMGN) with Buy recommendations, citing, among other things, favorable views...

News Image
19 days ago - Seeking Alpha

IMGN stock drops amid plans to launch $6K cancer drug (NASDAQ:IMGN)

Oncology-focused biotech ImmunoGen, Inc. (IMGN) shed ~12% on Tuesday after the company said it would launch the newly approved ovarian cancer drug Elahere "in a matter of days" at a...

News Image
2 months ago - Market News Video

ImmunoGen (IMGN) Shares Cross Above 200 DMA